Syntactx and QUNIQUE Form Strategic Partnership

December 14, 2020

Syntactx is very proud to announce that we are partnering with QUNIQUE to expand the global regulatory strategy efforts. Manufacturers of innovative therapies and devices face constantly-evolving global clinical and regulatory complexities. Our relationship with QUNIQUE will strengthen our ability to assist our clients with the design and execution of strategies that support product introduction and clinical acceptance on a global scale.

Combining our in-house FDA experience with QUNIQUE’s understanding of MDR through Dr. Bassil Akra’s team, we are confident that our clients worldwide will benefit from this partnership.

About Syntactx

Syntactx is a clinical research organization with expertise in complex interventional medical device and pharmaceutical trials across multiple therapeutic areas. Syntactx has a long history of synthesizing clinical evidence to enable broad market adoption of innovative products. For more information, visit www.syntactx.com.

About QUNIQUE

QUNIQUE is a consultancy organization that specializes in developing tailored concepts and solutions to support, maintain and improve the compliance of companies in the medical, in-vitro diagnostic and combination device sectors. For more information, visit www.quniquegroup.com.